No association of G-463A myeloperoxidase gene polymorphism with MPO-ANCA-associated vasculitis

Nephrology Dialysis Transplantation

Volumn 19, Issue 4, 2004, Pages 969-971

  Fiebeler, Anette ^a   Borgmann, Stefan ^c   Woywodt, Alexander ^b   Haller, Hermann ^b   Haubitz, Marion ^b  

^a FRANZ VOLHARD CLINIC   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

ANCA; Microscopic polyangiitis; Myeloperoxidase; Polymorphism; Vasculitis; Wegener's granulomatosis

Indexed keywords

ADENINE; GUANINE; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; SYSTEMIC VASCULITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PEROXIDASE; POLYMORPHISM, GENETIC; VASCULITIS;

EID: 1842575685     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh025     Document Type: Article

References (13)

1. Kallenberg CG, Rarok A, Stegeman CA. Genetics of ANCA-associated vasculitides. Cleve Clin J Med 2002; 69 [Suppl 2]: SII61-63
2. Gencik M, Meller S, Borgmann S, Fricke H. Proteinase 3 gene polymorphisms and Wegener's granulomatosis. Kidney Int 2000; 58: 2473-2477
3. Schreiber A, Busjahn A, Luft CF, Kettritz R. Membrane expression of proteinase 3 is genetically controlled. J Am Soc Nephrol 2002; 13: 172A
4. Rarok AA, Stegeman CA, Limburg PC, Kallenberg GM. Neutrophil membrane expression of proteinase 3 is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13: 2232-2238
5. Schonermarck U, Lamprecht P, Csernok E, Gross WL. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology 2001; 40: 178-184
6. Hagen EC, Daha MR, Hermans J et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-753
7. Cascorbi I, Henning S, Brockmoller J et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant -463A of the myeloperoxidase gene. Cancer Res 2000; 60: 644-649
8. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997; 57: 5001-5003
9. Charles LA, Caldas ML, Flak RJ, Terrell RS, Jennette JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 1991; 50: 539-546
10. Kallenberg CG. Autoantibodies to myeloperoxidase: Clinical and pathophysiological significance. J Mol Med 1998; 76: 682-687
11. Reumaux D, De Boer M, Duthilleul P, Roos D. Neutrophils from a completely myeloperoxidase-deficient donor are not activated by anti-MPO monoclonal antibodies. Clin Exp Immunol 2000; 120 [Suppl]: 40
12. Sham PC, Curtis D, MacLean CJ. Likelihood ratio tests for linkeage and linkeage disequilibrium: Asymptotic distribution and power. Am J hum Genet 1996; 58: 1093-1096
13. Reynolds WF, Stegeman CA, Cohen Tervaert JW. 463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol 2002; 103: 154-160